Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caris Life Sciences (CAI) Change in Receivables (2024 - 2025)

Caris Life Sciences (CAI) has 2 years of Change in Receivables data on record, last reported at $91.0 million in Q4 2025.

  • For Q4 2025, Change in Receivables rose 383.97% year-over-year to $91.0 million; the TTM value through Dec 2025 reached $83.7 million, changed N/A, while the annual FY2025 figure was $29.8 million, 11.91% down from the prior year.
  • Change in Receivables reached $91.0 million in Q4 2025 per CAI's latest filing, up from -$24.2 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $91.0 million in Q4 2025 and bottomed at -$24.2 million in Q3 2025.